ImmunityBio Inc
IBRX
Market Cap$6.07B
Close$
$-1.27
115.3% downside
Current Fair Value
115.3% downsideOvervalued by 115.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.07 Billion |
|---|---|
| Enterprise Value | $6.43 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-1.15 |
| Beta | 3.38 |
| Outstanding Shares | 677,003,411 |
| Avg 30 Day Volume | 11,639,182 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -10.41 |
|---|---|
| PEG | -9.0 |
| Price to Sales | - |
| Price to Book Ratio | -8.26 |
| Enterprise Value to Revenue | 10335.04 |
| Enterprise Value to EBIT | -17.43 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | -1.06 |
Revenue Sources
No data
ESG Score
No data
About ImmunityBio Inc
171 employees
CEO: Patrick Soon-Shiong NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms ...